![Figure 2 from Potential of nor-Ursodeoxycholic Acid in Cholestatic and Metabolic Disorders | Semantic Scholar Figure 2 from Potential of nor-Ursodeoxycholic Acid in Cholestatic and Metabolic Disorders | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/8c083303490d24d37a88317beed8b18de95ce5a0/3-Figure2-1.png)
Figure 2 from Potential of nor-Ursodeoxycholic Acid in Cholestatic and Metabolic Disorders | Semantic Scholar
![Figure 1 from Potential of nor-Ursodeoxycholic Acid in Cholestatic and Metabolic Disorders | Semantic Scholar Figure 1 from Potential of nor-Ursodeoxycholic Acid in Cholestatic and Metabolic Disorders | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/8c083303490d24d37a88317beed8b18de95ce5a0/2-Figure1-1.png)
Figure 1 from Potential of nor-Ursodeoxycholic Acid in Cholestatic and Metabolic Disorders | Semantic Scholar
![24-Nor Ursodeoxycholic Acid-d5 (major) Acyl-b-D-glucuronide | (3α,5β,7β)-3,7-Dihydroxy-24-norcholan-23-oic Acid-d5 1-O-Acyl-β-D-glucuronide; 24-Nor Ursodeoxycholic Acid-d5 1-O-Acyl-β-D-glucuronide; | C₂₉H₄₁D₅O₁₀ | TRC 24-Nor Ursodeoxycholic Acid-d5 (major) Acyl-b-D-glucuronide | (3α,5β,7β)-3,7-Dihydroxy-24-norcholan-23-oic Acid-d5 1-O-Acyl-β-D-glucuronide; 24-Nor Ursodeoxycholic Acid-d5 1-O-Acyl-β-D-glucuronide; | C₂₉H₄₁D₅O₁₀ | TRC](https://www.trc-canada.com/prod-img/N865312.png)
24-Nor Ursodeoxycholic Acid-d5 (major) Acyl-b-D-glucuronide | (3α,5β,7β)-3,7-Dihydroxy-24-norcholan-23-oic Acid-d5 1-O-Acyl-β-D-glucuronide; 24-Nor Ursodeoxycholic Acid-d5 1-O-Acyl-β-D-glucuronide; | C₂₉H₄₁D₅O₁₀ | TRC
![Chemical structure and hepatic glucuronidation of norUDCA. A, norUDCA... | Download Scientific Diagram Chemical structure and hepatic glucuronidation of norUDCA. A, norUDCA... | Download Scientific Diagram](https://www.researchgate.net/publication/38067368/figure/fig1/AS:394239646158848@1471005464371/Chemical-structure-and-hepatic-glucuronidation-of-norUDCA-A-norUDCA-is-a-synthetic-C-23.png)
Chemical structure and hepatic glucuronidation of norUDCA. A, norUDCA... | Download Scientific Diagram
![Norursodeoxycholic acid versus placebo in the treatment of non-alcoholic fatty liver disease: a double-blind, randomised, placebo-controlled, phase 2 dose-finding trial - The Lancet Gastroenterology & Hepatology Norursodeoxycholic acid versus placebo in the treatment of non-alcoholic fatty liver disease: a double-blind, randomised, placebo-controlled, phase 2 dose-finding trial - The Lancet Gastroenterology & Hepatology](https://www.thelancet.com/cms/attachment/794e1771-28bd-4544-bad6-677c5edad3c5/gr3_lrg.jpg)
Norursodeoxycholic acid versus placebo in the treatment of non-alcoholic fatty liver disease: a double-blind, randomised, placebo-controlled, phase 2 dose-finding trial - The Lancet Gastroenterology & Hepatology
![Norursodeoxycholic acid versus placebo in the treatment of non-alcoholic fatty liver disease: a double-blind, randomised, placebo-controlled, phase 2 dose-finding trial - The Lancet Gastroenterology & Hepatology Norursodeoxycholic acid versus placebo in the treatment of non-alcoholic fatty liver disease: a double-blind, randomised, placebo-controlled, phase 2 dose-finding trial - The Lancet Gastroenterology & Hepatology](https://www.thelancet.com/cms/attachment/8ddb887f-c37c-4d1a-bfeb-c50225ec9677/gr6.jpg)
Norursodeoxycholic acid versus placebo in the treatment of non-alcoholic fatty liver disease: a double-blind, randomised, placebo-controlled, phase 2 dose-finding trial - The Lancet Gastroenterology & Hepatology
![Biomolecules | Free Full-Text | Overview of Bile Acids Signaling and Perspective on the Signal of Ursodeoxycholic Acid, the Most Hydrophilic Bile Acid, in the Heart Biomolecules | Free Full-Text | Overview of Bile Acids Signaling and Perspective on the Signal of Ursodeoxycholic Acid, the Most Hydrophilic Bile Acid, in the Heart](https://www.mdpi.com/biomolecules/biomolecules-08-00159/article_deploy/html/images/biomolecules-08-00159-g003.png)
Biomolecules | Free Full-Text | Overview of Bile Acids Signaling and Perspective on the Signal of Ursodeoxycholic Acid, the Most Hydrophilic Bile Acid, in the Heart
![CAS No : 10538-55-3 | Product Name : Ursodeoxycholic Acid - Impurity G | Chemical Name : Cholic Acid | Pharmaffiliates CAS No : 10538-55-3 | Product Name : Ursodeoxycholic Acid - Impurity G | Chemical Name : Cholic Acid | Pharmaffiliates](https://www.pharmaffiliates.com/pimages/PA2104560.jpg)
CAS No : 10538-55-3 | Product Name : Ursodeoxycholic Acid - Impurity G | Chemical Name : Cholic Acid | Pharmaffiliates
![Norursodeoxycholic acid versus placebo in the treatment of non-alcoholic fatty liver disease: a double-blind, randomised, placebo-controlled, phase 2 dose-finding trial - The Lancet Gastroenterology & Hepatology Norursodeoxycholic acid versus placebo in the treatment of non-alcoholic fatty liver disease: a double-blind, randomised, placebo-controlled, phase 2 dose-finding trial - The Lancet Gastroenterology & Hepatology](https://www.thelancet.com/cms/attachment/4e3efa58-1666-477e-a248-4bd12072967e/gr5.jpg)
Norursodeoxycholic acid versus placebo in the treatment of non-alcoholic fatty liver disease: a double-blind, randomised, placebo-controlled, phase 2 dose-finding trial - The Lancet Gastroenterology & Hepatology
![Mechanism of action of three potential therapeutic drugs-ursolic acid,... | Download Scientific Diagram Mechanism of action of three potential therapeutic drugs-ursolic acid,... | Download Scientific Diagram](https://www.researchgate.net/publication/311917773/figure/fig1/AS:443902764294144@1482846074276/Mechanism-of-action-of-three-potential-therapeutic-drugs-ursolic-acid.png)
Mechanism of action of three potential therapeutic drugs-ursolic acid,... | Download Scientific Diagram
![Norursodeoxycholic acid versus placebo in the treatment of non-alcoholic fatty liver disease: a double-blind, randomised, placebo-controlled, phase 2 dose-finding trial - The Lancet Gastroenterology & Hepatology Norursodeoxycholic acid versus placebo in the treatment of non-alcoholic fatty liver disease: a double-blind, randomised, placebo-controlled, phase 2 dose-finding trial - The Lancet Gastroenterology & Hepatology](https://www.thelancet.com/cms/attachment/c1eccfbc-fb19-4d1c-8f17-a5c255873359/gr1_lrg.jpg)